Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
High Demand Triggers Shipment Curb for G-Lasta Biosimilars
Companies marketing Japan’s first biosimilars of G-Lasta (pegfilgrastim), a long-acting G-CSF agent, are putting the brakes on shipments of these products just over three months after their launch owing to high demand. Subject to the shipment restrictions are Pegfilgrastim BS…
To read the full story
Related Article
- Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
December 13, 2023
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
BUSINESS
- Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
- Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026
- PeptiDream Kicks Off PII for Radiotherapeutic Targeting Prostate Cancer
February 6, 2026
- Daiichi Sankyo Starts PI/PII Trial of ADC DS3790 in Blood Cancers
February 6, 2026
- Keytruda Extends Lead to 28 Months in January Drug Ranking: Encise
February 6, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…